Analysts Offer Predictions for Astrazeneca FY2026 Earnings

Astrazeneca Plc (NYSE:AZN) – Stock analysts at Erste Group Bank decreased their FY2026 earnings per share estimates for shares of Astrazeneca in a research note issued to investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now expects that the company will post earnings per share of $10.31 for the year, down from their prior forecast of $10.52. The consensus estimate for Astrazeneca’s current full-year earnings is $10.22 per share. Erste Group Bank also issued estimates for Astrazeneca’s FY2027 earnings at $11.50 EPS.

Several other equities research analysts also recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Finally, Weiss Ratings downgraded Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Trading Down 2.8%

NYSE AZN opened at $164.14 on Monday. Astrazeneca has a one year low of $137.23 and a one year high of $212.71. The company’s 50 day moving average price is $181.80 and its 200 day moving average price is $188.30. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The firm has a market capitalization of $254.56 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 1.38 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.

Institutional Trading of Astrazeneca

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC raised its stake in shares of Astrazeneca by 93.2% in the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares in the last quarter. AQR Capital Management LLC grew its stake in Astrazeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after purchasing an additional 11,690 shares in the last quarter. Amundi grew its stake in Astrazeneca by 54.4% in the second quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after purchasing an additional 3,618 shares in the last quarter. Jump Financial LLC increased its holdings in Astrazeneca by 898.4% in the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after buying an additional 30,125 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in Astrazeneca by 1.2% in the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after buying an additional 559 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.